Xoma Has Acquired The Royalty And Milestone Rights Associated With Two Assets From LadRx, Including Arimoclomol And Aldoxorubicin, For $5M, For Orphan Disease Niemann-pick Disease Type C And Phase 2 Oncology, Respectively
Xoma Has Acquired The Royalty And Milestone Rights Associated With Two Assets From LadRx, Including Arimoclomol And Aldoxorubicin, For $5M, For Orphan Disease Niemann-pick Disease Type C And Phase 2 Oncology, Respectively
Xoma以500萬美元的價格收購了與LadRx的兩項資產（包括阿里莫洛莫和阿多柔比星）相關的特許權使用費和里程碑權，分別用於孤兒病尼曼-皮克病C型和2期腫瘤學
Xoma Has Acquired The Royalty And Milestone Rights Associated With Two Assets From LadRx, Including Arimoclomol And Aldoxorubicin, For $5M, For Orphan Disease Niemann-pick Disease Type C And Phase 2 Oncology, Respectively
Xoma以500萬美元的價格收購了與LadRx的兩項資產（包括阿里莫洛莫和阿多柔比星）相關的特許權使用費和里程碑權，分別用於孤兒病尼曼-皮克病C型和2期腫瘤學
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。